美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

避孕概念

2,785.02

+54.552.00%

漲家數：3

跌家數：2

平家數：- -

市盈率：- -

高：2,785.24

開：2,747.96

低：2,709.44

收：2,730.47

成交量：568.07萬

成交額：1.15億

市值：444.94億

流通市值：415.47億

資料載入中...

梯瓦製藥（TEVA）完成49億美元等值優先票據定價募資用於置換多筆存量債券

曼恩凱德生物醫療——將為體重管理研究提供至1B期的開發與生產支持

曼恩凱德生物醫療將獲得Rose Pharma股權及未來淨銷售額潛在特許權使用費

曼恩凱德生物醫療與Rose Pharma簽署許可合作協議，共同開發吸入式速效短效GLP-1藥物用於體重管理

Veru推進口服Sabizabulin進入計劃中的2期臨床試驗，臨床前數據揭示其對Daraxonrasib（Revolution Medicines' Rasonque™）耐藥胰腺癌具有強效抗癌活性

梯瓦製藥美股盤前上漲3.5%，免疫疾病藥物中期試驗達標

梯瓦製藥美國上市盤前股價上漲3.5%，此前該公司免疫紊亂藥物在中期試驗中達到主要終點。

梯瓦製藥（TEVA）與Royalty Pharma（RPRX）合作抗體藥物TEV'408迎重大臨床突破

特瓦公司一款免疫系統疾病藥物在中期臨床試驗中達到了主要目標

梯瓦製藥Tev‘408在2a期研究中顯著預防麩質誘導損傷

Trailpeak 重磅登場：Teva 首款高性能日常越野跑鞋，攜手品牌探險運動員聯合打造

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/BK4584/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"避孕概念","latestPrice":2785.0151,"timestamp":1789156799999,"preClose":2730.4697,"halted":0,"volume":5680744,"delay":0,"changeRate":0.019977,"floatShares":0,"shares":0,"eps":0,"marketStatus":"休市中","change":54.54541,"latestTime":"09-11 16:00:00 EDT","open":2747.9634,"high":2785.2388,"low":2709.4424,"amount":115106407.669124,"amplitude":0.027759,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.656322,"peRate":69.731563,"turnoverRate":0.003956,"increases":3,"decrements":2,"flats":0,"marketCap":44494395808,"floatMarketCap":41546748035},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2785.2388,"amplitude":0.027759,"preClose":2730.4697,"low":2709.4424,"pbRate":"5.656322","latestPrice":2785.0151,"volume":5680744,"delay":0,"open":2747.9634,"prevYearClose":2379.9924,"prevWeekClose":2734.7136,"prevMonthClose":2714.4358,"prevQuarterClose":2562.5076,"fiveDayClose":2753.218,"twentyDayClose":2738.6797,"sixtyDayClose":2484.0588,"secType":"PLATE","market":"US","turnoverRate":0.003956,"peRate":69.731563,"marketCap":44494395808,"floatMarketCap":41546748035,"timestamp":1789156799999,"nameCN":"避孕概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":3,"down":2,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666560146","title":"梯瓦製藥（TEVA）完成49億美元等值優先票據定價 募資用於置換多筆存量債券","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560146","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560146?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:00","pubTimestamp":1789038049,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 完成总规模约49亿美元等值优先票据的发行定价。本次发行共分为五个批次：10亿欧元2033年到期票据，票面利率4.25%；5亿欧元2036年到期票据，票面利率4.625%；10亿美元2034年到期票据，票面利率5.5%；10亿美元2037年到期票据，票面利率5.75%；12亿美元2032年到期票据，票面利率5.25%。梯瓦制药计划将本次募资净额，叠加公司现有现金，用于赎回存量债务、支付相关发行费用以及一般企业用途。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ODI2NGE1NjlmODgxZDI1NzFmMmQ4ODQzNDA1OTI5NjU2Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305896","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4566","BK4584","LU1983299246.USD","TEVA","BK4588","LU2324357040.USD","BNDW","BK4559","BK4007","BK4596","BK4585","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164873650","title":"曼恩凱德生物醫療——將為體重管理研究提供至1B期的開發與生產支持","url":"https://stock-news.laohu8.com/highlight/detail?id=1164873650","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164873650?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:32","pubTimestamp":1788949976,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗宣布，将为一项目前处于临床1B阶段的体重管理研究提供开发及制造支持。此举不仅彰显了MannKind在生物制药领域的专业实力，也预示着其进一步扩展在代谢性疾病治疗方向的战略布局。作为一家专注于创新药物递送技术的企业，MannKind此前已在糖尿病管理领域积累了丰富经验。截至目前，关于该研究的更多细节尚未完全披露，但市场对这一消息反应积极，投资者对MannKind跨界布局的潜力充满期待。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4584","MNKD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168149315","title":"曼恩凱德生物醫療將獲得Rose Pharma股權及未來淨銷售額潛在特許權使用費","url":"https://stock-news.laohu8.com/highlight/detail?id=1168149315","media":"美股速递","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168149315?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:31","pubTimestamp":1788949896,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗公司——即将获得Rose Pharma的股权权益，并有望从未来净销售额中获取潜在的特许权使用费。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","MNKD","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195249565","title":"曼恩凱德生物醫療與Rose Pharma簽署許可合作協議，共同開發吸入式速效短效GLP-1藥物用於體重管理","url":"https://stock-news.laohu8.com/highlight/detail?id=1195249565","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195249565?lang=zh_tw&edition=fundamental","pubTime":"2026-09-09 18:31","pubTimestamp":1788949892,"startTime":"0","endTime":"0","summary":"曼恩凯德生物医疗（MannKind）与Rose Pharma Inc宣布达成一项许可与合作协议，聚焦于开发一种吸入型、快速起效且作用时间较短的GLP-1药物，旨在用于体重管理领域。\n根据协议内容，双方将整合各自优势资源，共同推进这一创新疗法的研发进程。该候选药物采用吸入给药方式，区别于传统注射剂型，有望为患者提供更为便捷的治疗选择。其快速起效与短时作用的特点，或能为体重管理方案带来新的思路。\n合作双方表示，此次携手旨在加速该药物的临床开发与后续商业化进程，以应对全球范围内日益增长的肥胖及相关代谢疾病治疗需求。协议的更多细节，包括财务条款与具体分工，暂未对外完全披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNKD","BK4584","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144952887","title":"Veru推進口服Sabizabulin進入計劃中的2期臨床試驗，臨床前數據揭示其對Daraxonrasib（Revolution Medicines' Rasonque™）耐藥胰腺癌具有強效抗癌活性","url":"https://stock-news.laohu8.com/highlight/detail?id=1144952887","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144952887?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 20:18","pubTimestamp":1788869895,"startTime":"0","endTime":"0","summary":"Veru公司宣布，基于令人振奋的临床前研究结果，将积极推进口服药物Sabizabulin迈向计划中的2期临床试验阶段。该项研究数据显示，该候选药物在对抗人类Daraxonrasib（即Revolution Medicines旗下Rasonque™）耐药的胰腺癌方面，展现出显著的抗癌效力。这一进展为那些对现有疗法产生耐药性的患者群体带来了新的希望，也标志着Veru在肿瘤治疗领域的布局又向前迈出了坚实一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4584","BK4007","VERU","BK4557"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188485546","title":"梯瓦製藥美股盤前上漲3.5%，免疫疾病藥物中期試驗達標","url":"https://stock-news.laohu8.com/highlight/detail?id=1188485546","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188485546?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:13","pubTimestamp":1788351207,"startTime":"0","endTime":"0","summary":"梯瓦制药（Teva Pharmaceutical）在美国上市的股票在盘前交易中上涨了3.5%。此前，该公司宣布其治疗免疫系统疾病的药物在中期临床试验中达到了主要目标。这一消息提振了投资者信心，推动股价在盘前时段走高。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","BK4588","BK4559","BK4585","LU2324357040.USD","BK4557","BK4007","TEVA","BK4584","LU1983299246.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811810","title":"梯瓦製藥美國上市盤前股價上漲3.5%，此前該公司免疫紊亂藥物在中期試驗中達到主要終點。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811810","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811810?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:11","pubTimestamp":1788351064,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4557","BK4566","BK4585","BK4007","IPOS","LU1983299246.USD","TEVA","BK4596","BK4584","BK4559","LU2324357040.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333811","title":"梯瓦製藥（TEVA）與Royalty Pharma（RPRX）合作抗體藥物TEV'408迎重大臨床突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333811","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664333811?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:07","pubTimestamp":1788350836,"startTime":"0","endTime":"0","summary":"金吾财讯 | 梯瓦制药 与Royalty Pharma宣布，双方合作开发的抗白细胞介素-15抗体药物TEV'408在治疗成人乳糜泻的2a期临床试验中取得积极结果。在给药第8周时，与安慰剂组相比，TEV'408在统计学上显著且临床上有效地预防了由麸质诱发的肠道损伤。根据“乳糜泻症状日记”显示，接受TEV'408治疗的患者其胃肠道症状评分明显低于安慰剂组。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/ODY4OWQ3Mzc3NDBiZmZiN2U4NjgyMDY5NTE3ODY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305631","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IHE","BK4596","LU1983299246.USD","BK4007","TEVA","BK4557","PBE","BK4559","BK4585","RPRX","BK4588","BK4584","LU2324357040.USD","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664081923","title":"特瓦公司一款免疫系統疾病藥物在中期臨床試驗中達到了主要目標","url":"https://stock-news.laohu8.com/highlight/detail?id=2664081923","media":"路透中文","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664081923?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:02","pubTimestamp":1788350525,"startTime":"0","endTime":"0","summary":"特瓦公司一款免疫系统疾病药物在中期临床试验中达到了主要目标路透9月2日-以色列制药商梯瓦制药工业公司周三表示，其一款试验性药物有助于预防成人乳糜泻患者因麸质引发的肠道损伤，达到了中期临床试验的主要目标。乳糜泻是一种自身免疫性疾病，其中麸质会引发免疫反应，从而损伤小肠。TEV-408目前还正在针对白癜风进行测试，并计划针对该皮肤病启动另一项中期临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260902:nL4T44U120:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4596","LU2324357040.USD","RPRX","TEVA","BK4585","BK4559","BK4007","BK4557","IHE","PBE","BK4584","BK4566","LU1983299246.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141512147","title":"梯瓦製藥Tev‘408在2a期研究中顯著預防麩質誘導損傷","url":"https://stock-news.laohu8.com/highlight/detail?id=1141512147","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1141512147?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:07","pubTimestamp":1788347268,"startTime":"0","endTime":"0","summary":"梯瓦制药宣布，其研发的Tev‘408在2a期临床试验中展现出统计学上显著的预防效果，能够有效阻止麸质引发的肠道损伤。这一研究结果备受关注，为乳糜泻患者带来了新的希望。梯瓦制药的这项突破性进展，不仅验证了Tev‘408的作用机制，更为后续更大规模的临床研究奠定了坚实基础。业内专家指出，这一成果有望为目前缺乏有效治疗手段的乳糜泻患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4566","BK4584","BK4585","TEVA","BK4559","BK4557","BK4588","LU2324357040.USD","BK4596","LU1983299246.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103791404","title":"Trailpeak 重磅登場：Teva 首款高性能日常越野跑鞋，攜手品牌探險運動員聯合打造","url":"https://stock-news.laohu8.com/highlight/detail?id=1103791404","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103791404?lang=zh_tw&edition=fundamental","pubTime":"2026-09-01 21:03","pubTimestamp":1788267798,"startTime":"0","endTime":"0","summary":"Trailpeak 正式亮相——这是 Teva 品牌推出的首款专为日常越野跑打造的高性能跑鞋。该鞋款并非闭门造车，而是与品牌旗下的“探险运动员理事会”深度共创的结晶。从设计理念到功能细节，Trailpeak 都凝聚了这群长期活跃于山野间的运动员的真实反馈与实战经验。Trailpeak 的面世，或许将重新定义“日常越野跑鞋”的标准，成为跑者们鞋柜中值得信赖的新选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4566","BK4146","BK4596","LU1983299246.USD","LU2324357040.USD","TEVA","BK4559","DECK","LU0266013472.USD","BK4557","BK4567","BK4584","BK4588","STYL","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":11,"code":"91000000","status":"200"}]}}